Effects of clozapine on awareness of illness and cognition in schizophrenia

Psychiatry Research

Volumn 86, Issue 3, 1999, Pages 239-249

  Pallanti, Stefano ^a,b   Quercioli, Leonardo ^a   Pazzagli, Adolfo ^b  

^a Psichiatria P   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Atypical vs. typical antipsychotics; Cognitive function; Evoked potentials; Extrapyramidal side effects; P300 component

Indexed keywords

CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; LORAZEPAM; NEUROLEPTIC AGENT; VENLAFAXINE;

ADULT; ARTICLE; AWARENESS; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVENT RELATED POTENTIAL; EVOKED RESPONSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MENTAL DISEASE; NEGATIVE SYNDROME; PERFORMANCE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COGNITION; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; EVENT-RELATED POTENTIALS, P300; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF CONCEPT; TREATMENT OUTCOME;

EID: 0032806281     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(99)00033-5     Document Type: Article

References (44)

1. Abate C., Luk D., Gagne E., Roeder R.G., Curran T. Fos and Jun cooperate in transcriptional regulation via heterologous activation domains. Molecular and Cellular Biology. 10:1990;5532-5535.
2. Addington J., Addington D., Maticka-Tyndale E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophrenia Research. 5:1991;123-134.
3. Amador X.F., Strauss D.H., Scott A., Yale M.S.W., Flaum M.M., Endicott J., Gorman J.M. Assessment of insight in psychosis. American Journal of Psychiatry. 150:1993;873-879.
4. Amador X.F., Flaum M.M., Andreasen N.C., Strauss D.H., Yale S.A., Clark S.C., Gorman J.M. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Archives of General Psychiatry. 51:1994;826-836.
5. th edn. 1994;American Psychiatric Press, Washington, DC.
6. Andreasen N.C. Moscarelli M., Maffei C. Schizofrenia. Scale per la valutazione dei Sintomi Positivi e Negativi. 1987;Cortina, Milan, Italy.
7. Berman I., Viegner B., Merson A., Allan E., Pappas D., Green A.I. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophrenia Research. 25:1997;1-10.
8. Blackwood D., Whalley L., Christie J., Blackburn I., St Clair D., McInnes A. Changes in auditory P3 event-related potential in schizophrenia and depression. British Journal of Psychiatry. 150:1987;154-160.
9. Buchanan R.W., Holstein C., Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry. 36:1994;717-725.
10. Cameron D.S., Duman R.S., Deutch A.Y. Clozapine induces Fos expression in pyramidal cells and interneurons in the prefrontal cortex in a regionally specific manner. Society of Neuroscience Abstracts. 19:1993;1213.
11. Collins A.A., Remington G.J., Coulter K., Birkett K. Insight, neurocognitive function and symptom clusters in chronic schizophrenia. Schizophrenia Research. 27:1997;37-44.
12. Deutch A.Y., Lee M.C., Iadarola M.J. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Molecular and Cellular Neurosciences. 3:1992;332-341.
13. Duncan C.C. Event-related brain potentials: a window on information processing in schizophrenia. Schizophrenia Bulletin. 14:1988;199-203.
14. Duncan C.C. Current issues in the application of P300 to research on schizophrenia. Straube E.R., Hahlweg K. Schizophrenia: Concepts, Vulnerability and Intervention. 1990;117-134 Springer-Verlag, New York.
15. Ford J.M., White P.M., Csernansky J.G., Faustman W.O., Roth W.T., Pfefferbaum A. ERPs in schizophrenia: effects of antipsychotic medication. Biological Psychiatry. 36:1994;153-170.
16. Friedman D. Endogenous scalp-recorded brain potentials in schizophrenia: a methodological review. Nasrallah H.A. Handbook of Schizophrenia, Vol. 5. 1991;91-127 Elsevier, Amsterdam.
17. Gallhofer B., Bauer U., Lis S., Krieger S., Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with antipsychotic agents and conventional neuroleptic drugs. European Neuropsychopharmacology. 6:1996;13-20.
18. Goldberg T.E., Weinberger D.R. The effects of clozapine on neurocognition: an overview. Journal of Clinical Psychiatry. 55, Suppl. B:1994;88-90.
19. Grace J., Bellus S.B., Raulin M.L., Herz M.I., Priest B.L., Brenner V., Donnelly K., Smith P., Gunn S. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatric Services. 47:1996;41-45.
20. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive function and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry. 34:1993;702-712.
21. Hegerl U., Juckel G., Müller Schubert A., Pietzcker A., Gaebel W. Schizophrenics with small P300: a subgroup with a neurodevelopmental disturbance and a risk for tardive dyskinesia? Acta Psychiatrica Scandinavica. 91:1995;120-125.
22. Hirayasu Y., Asato N., Ohta H., Hokama H., Arakaki H., Ogura C. Abnormalities of auditory event-related potentials in schizophrenia prior to treatment. Biological Psychiatry. 43:1998;244-253.
23. Hoff A.L., Faustman W.O., Wieneke M., Espinoza S., Costa M., Wolkowitz O., Csernansky J.G. The effects of clozapine on symptom reduction, neurocognitive function and clinical management in treatment refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 5(4):1996;361-369.
24. Johnson R. On the neural generators of the P300 component of the event-related potential. Psychophysiology. 30:1993;90-97.
25. Juckel G., Müller Schubert A., Gaebel W., Hegerl U. Residual symptoms and P300 in schizophrenic patients. Psychiatry Research. 65, 1:1996;23-32.
26. Kane J.M., Safferman A., Pollack S., Johns C., Szymanski S., Kronig M., Lieberman J.A. Clozapine, negative symptoms, and extrapyramidal side effects. Journal of Clinical Psychiatry. 55:1994;74-77.
27. Kemp R., David A. Psychological predictors of insight and compliance in psychotic patients. British Journal of Psychiatry. 169:1996;444-450.
28. Kemp R.A., Lambert T.J.R. Insight in schizophrenia and its relationship to psychopathology. Schizophrenia Research. 18:1995;21-28.
29. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry. 55,Suppl. B:1994;82-87.
30. McEvoy J., Hartman M., Gottlieb D., Goodwin S., Apperson L., Wilson W. Common sense, insight and neuropsychological test performance in schizophrenic patients. Schizophrenia Bulletin. 22(4):1996;635-640.
31. Menditto A.A., Beck N.C., Stuve P., Fisher J.A., Stacy M., Logue M.B., Baldwin L.J. Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients. Psychiatric Services 4. 1:1996;46-51.
32. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes Fos and Jun. Annual Review of Neuroscience. 14:1991;421-451.
33. O'Donnell B.F., Faux S.F., McCarley R.W., Kimble M.O., Salisbury D.F., Nestor P.G., Kikinis R., Jolesz F.A., Shenton M.E. Increased rate of P300 latency prolongation with age in schizophrenia: electrophysiological evidence for a neurodegenerative process. Archives of General Psychiatry. 52:1995;544-549.
34. Pallanti S., Quercioli L., Pazzagli A. Relapse in young schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. American Journal of Psychiatry. 154:1997;792-798.
35. Pritchard W.S. Cognitive event-related potential correlates of schizophrenia. Psychological Bulletin. 100:1986;43-66.
36. Romani A., Merello S., Gozzoli L., Zerbi F., Grassi M., Cosi V. P300 and CT scan in patients with chronic schizophrenia. British Journal of Psychiatry. 151:1987;506-513.
37. Schall U., Catts S.V., Chaturvedi S., Redenbach J., Karayanidis F., Ward P.B. The effect of clozapine on psychometric and event-related potential (ERP) measures on cognitive dysfunction in schizophrenia. (Abstract) Schizophrenia Research. 15:1995;164.
38. Schwartz R.C., 1998. 'Symptomatology and insight in schizophrenia'. Psychological Reports 82, 227-233.
39. Simpson G.M., Angus C.B., Angus J.W.S. A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica. 212:1970;11-19.
40. Spitzer R.L., Endicott J., Robins E. Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry. 35:1978;773-782.
41. Startup M. Insight and cognitive deficits in schizophrenia: evidence for a curvilinear relationship. Psychological Medicine. 26:1996;1277-1281.
42. Stolar N., Berenbaum H., Banich M.T., Barch D. Neuropsychological correlates of alogia and affective flattening in schizophrenia. Biological Psychiatry. 35:1994;164-172.
43. Verdoux H., Magnin E., Bourgeois M. Neuroleptic effects on neuropsychological test performance in schizophrenia. Schizophrenia Research. 14:1995;133-139.
44. Young D.A., Davila R., Scher H. Unawareness of illness and neuropsychological performance in chronic schizophrenia. Schizophrenia Research. 10:1993;117-124.